Mts105 for Advanced Hepatocellular Carcinoma

This study is testing a new treatment called Mts105 for people with advanced liver cancer (hepatocellular carcinoma, or HCC) whose cancer has stopped responding to standard therapies. Mts105 is a targeted treatment designed to attack cancer cells that carry a protein called GPC3. **You may be eligible if...** - You have confirmed advanced liver cancer (HCC), not including uncommon subtypes - Your cancer cells test positive for the GPC3 protein - Your cancer has progressed after trying at least one immune checkpoint inhibitor and one targeted therapy (such as a tyrosine kinase inhibitor) - You are 18 or older and in reasonable general health **You may NOT be eligible if...** - Your cancer is a rare subtype (such as fibrolamellar or sarcomatoid HCC) - You have not yet tried standard systemic treatments - You have serious liver disease, major infections, or other significant health conditions - Your cancer has spread to the brain Talk to your doctor to see if this trial is right for you.